AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05289674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Calorie Formula
Description: The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia
Study NCT06407206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub occipital muscle inhibition technique and conventional therapy
Description: Patient is in supine position Therapist sits near the head of the participant and places his hand below the head of the participant With the pads of hand therapist palpates the arch of atlas between the occipital protuberance and spinous process of axis and place the middle and ring finger over it by flexing the metacarpophalangeal joint in 90 degrees of flexion, base of skull will rest on hands Pressure is exerted in upward direction towards the therapist and is maintained for two minutes so that the muscle scan relax Participants are guided to keep their eyes close in order to avoid movement which affects the tone of sub occipital muscle
Study NCT06407206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: Transcutaneous electrical nerve stimulation at lower back and hamstring muscles (pulse rate: 4Hertz, pulse duration: 150µs for 15mins) Hot pack ( 15mins),Ankle pumps (15 reps with 5 sec hold), Knee Range of motions (flexion and extension,10 reps),Quadriceps set (10 reps,5 sec hold),Vastus Medialis oblique (10 reps 5 sec hold),Gluteus sets (10 reps, 5 sec hold),Single knee to chest (10 reps with 10 sec hold) McKenzie exercises (10 reps with 10 sec hold and 10 sec rest),Stretching of calf and hamstring muscles (passive stretching,7 reps with 5 sec hold).
Study NCT05462093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan sequences
Description: Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
Study NCT05462093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liver Multiscan analysis
Description: Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
Study NCT05462093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRCP+
Description: Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
Study NCT06656429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal Epidural Steroid Injections
Description: Transforaminal Epidural Steroid Injections
Study NCT05174624 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04245163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The intervention program will include 3 phases. At phase 1 a presentation on Microsoft PowerPoint in order to increase the general knowledge about glaucoma. At phase 2 a video and a one on one teaching to develop skills of administering the eye drops in a correct and systematic way. At phase 3, a discussion in order to identify cues to action that can easily be adopted by the patient in his/her daily routine, (such as, how to remember to put in drops) will take place.
Study NCT05735054 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic thyroidectomy
Description: the patients who underwent endoscopic transaxillary thyroidectomy
Study NCT06293144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
Study NCT04691232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Autologous, ex vivo expanded, regulatory T cells
Study NCT06188546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
Study NCT06188546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
Study NCT06390215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Readiness Coaching Intervention
Description: Two 1-hr School Readiness Coaching Session
Study NCT05122715 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Additional PET/CT Scan
Description: The subject will undergo two PET/CT scans, one on the DMI scanner and one on the OMNI scanner.
Study NCT06413329 — intervention group
Intervention type: BEHAVIORAL
Intervention: preoperative physical activity level within 3 months
Description: The exercise compliance criteria are moderate exercise of at least 150 minutes per week or high-intensity exercise of at least 75 minutes per week.
Study NCT04994236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
Description: The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
Study NCT05850507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells).
Study NCT05850507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus protein vaccine (CHO cells)
Description: Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person dose Recombinant new coronavirus vaccine (CHO cells) .
Study NCT05575310 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Articular knee surface replacement
Study NCT06321575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Description: Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.
Study NCT05812716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resiLIR Healthcare Professionals
Description: Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life.
Study NCT06521489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical High Flow Nasal Cannula Oxygenation
Description: Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
Study NCT06521489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional High Flow Nasal Cannula Oxygenation
Description: Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
Study NCT06084806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-ARAG PET
Description: Two imaging sessions
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Performance of the NIRS biosensor will be explored in comparison to this commercial wearable.
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Douglas Bag
Description: The Douglas Bag will be used for inducing hypercapnia.
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periflux 6000 EPOS
Description: Tissue oxygen saturation measured by the Periflux 6000 will be compared with peripheral tissue saturation measured with the NIRS biosensor both at rest and during the induced hypercapnia, paced breathing and breath holding.
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOPAC
Description: The BIOPAC system will be used to record the PPG signal, cardiovascular hemodynamics, and respiratory parameters in order to noninvasively monitor the heart rate, heart rate variability, respiratory rate, respiratory effort index, and arterial oxygen saturation.
Study NCT06740370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Study NCT06740370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
Study NCT06186128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Basic Income
Description: Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
Study NCT06498713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg Oral Tablet
Description: 650 mg pills
Study NCT06498713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650mg Liquid
Description: 650 mg liquid
Study NCT06498713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD pump
Description: Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.
Study NCT05773365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENG block with or without local anaesthetic infiltration
Description: As mentioned.
Study NCT05773365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENG block with or without local anaesthetic infiltration
Description: As mentioned.
Study NCT05870787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swede score colposcopy
Description: New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination [RSVpreF+BNTb162b2]
Description: Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Bivalent BNT162b2 given as an intramuscular injection
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Bivalent BNT162b2 given as an intramuscular injection
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVpreF
Description: RSVpreF given as an intramuscular injection
Study NCT06400355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery
Study NCT06400355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
Study NCT04807439 — intervention group
Intervention type: DEVICE
Intervention: SYNERGY XLV (Megatron) Coronary Stent System
Description: The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
Study NCT04926805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP with Mask A
Description: CPAP mask
Study NCT04926805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with Mask B
Description: CPAP mask
Study NCT06427161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT application
Description: The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.
Study NCT06427161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dextrose injection
Description: 25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
Study NCT05442021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neubie Direct Current Electrical Stimulation Device
Description: Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
Study NCT05442021 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSVpreF given as an intramuscular injection
Study NCT05417113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: liposomal bupivacaine
Study NCT05417113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.25% in ESP blocks
Study NCT05417113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine 0.25% in ESP blocks
Study NCT05370326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Opioid Stewardship Program
Description: The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Licensed QIV given as an intramuscular injection
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV
Description: Licensed QIV given as an intramuscular injection
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)
Study NCT05886777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)
Study NCT05405712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone App
Description: App-based peer support program, used in conjunction with standard outpatient treatment
Study NCT05053828 — intervention group
Intervention type: DRUG
Intervention: Antiplatelet Drug
Description: Antiplatelet drugs and agents
Study NCT06061614 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: NGGT002
Study NCT05296278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-323 combined with bevacizumab plus Platinum
Description: IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
Study NCT04462146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Self Applied Treatment Program
Description: It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention
Study NCT04462146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videoconference treatment with a therapist
Description: It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
Study NCT06324591 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection biological sample and analysis
Description: collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
Study NCT05124548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep diagnostics
Description: On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
Study NCT06076590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance fluid
Description: Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
Study NCT06076590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintenance fluid
Description: Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
Study NCT05184439 — intervention group
Intervention type: PROCEDURE
Intervention: Adductor magnus tenodesis for recurrent patellar dislocation
Description: In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
Study NCT05934188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: The Magnetic Resonance Imaging protocol will comprise both structural and functional sequences.
Study NCT05934188 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological protocol
Description: Neuropsychological tests will be administered to participants to assess general cognitive state and a range of high-level cognitive functions (memory, executive, language). In addition, disease-specific tests will be administered to patients to investigate disease staging and the level of disability and autonomy.
Study NCT05934188 — intervention group
Intervention type: BEHAVIORAL
Intervention: Eating habits
Description: Information on eating habits will be derived from food questionnaires.
Study NCT05306288 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days from enrollment.
Study NCT05907421 — intervention group
Intervention type: BEHAVIORAL
Intervention: Acceptance mindset
Description: Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowmet
Description: Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.
Study NCT05035420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
Study NCT05145465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not.